KHIDI Health Industry R&D Promotion (umbrella)

KHIDI Health Industry R&D Promotion sits under the Korea Health Industry Development Institute and its Ministry of Health and Welfare remit. KHIDI plans, evaluates, and manages domestic healthcare R&D in South Korea, with a focus on new drugs, medical devices, regenerative medicine, and AI- and big-data-driven medical technology. The program is a grant route, runs annually, and is centered on Korea-based applicants. The call structure allows for-profit firms, universities, and research organizations, requires consortia, and uses the Korean-language EPS portal. The umbrella also covers drug R&D, medical device industry development, smart hospitals, and regenerative medicine. KHIDI's published results show the kind of work it backs: 30 new-drug cases, 213 medical-device cases, 79 international technology transfers, and 679 clinical-trial cases. Proposals move through planning, selection, management, and performance review, so applicants need a clear development plan and a credible path to commercialization. The program fits teams aligned with public-health priorities such as infectious disease, dementia, and mental health.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.